Giuseppe Ronzitti
  • E-mail :[email]
  • Phone : +33 781671485
  • Location : Fontainebleau, France
Last update 2022-03-05 08:19:33.044

Giuseppe Ronzitti PhD in Biochemistry, HDR

Course and current status

2019 – now        INSERM CRCN researcher and Team leader Immunology and liver gene transfer, Genethon and UMR_951, Evry, France

2017 – 2019        Group Leader Immunology and liver gene transfer, Genethon and UMR_951, Evry, France

2016 – 2017        MC Fellowship in Gene therapy, Genethon, Evry, France

2013 – 2015        Post-Doc in Gene therapy, Genethon, Evry, France          

2008 – 2013        Post-Doc in Neuroscience, Italian institute of Technology, Genova, Italy 

2003 – 2008        Ph.D. in Biochemistry, University of Bologna, Italy

1998 – 2003        B.S. in Biotechnology, University of Modena, Italy

Scientific summary

Dr. Ronzitti published 39 original research manuscripts with a cumulative impact factor of 289 that received more than 2000 citations. He also contributed to eight review articles, four book chapters and seven commentaries. Importantly, Dr Ronzitti authored sixteen patents on the development of AAV-based gene therapy strategies.  

At the end of 2013, after a PhD in Biochemistry and a first post-doc in neuroscience, Dr. Ronzitti moved to Genethon, France, to join the laboratory of Dr. Mingozzi. In this position, he was involved in the pre-clinical evaluation and optimization of an AAV-based treatment for the Crigler-Najjar syndrome that is now in the clinic (NCT03466463). He also participated to the development of a liver-targeted gene therapy for Pompe disease. In 2015 he was awarded with a Marie Curie Skłodowska Fellowship on the development of a proof of concept for the treatment of GSDIII. Since then his research has been focused on the development of AAV gene therapy approaches for metabolic diseases. 

Since 2018, Dr. Ronzitti is appointed as head of the Immunology and Liver gene transfer team at Genethon.

In 2019 Dr. Ronzitti has been appointed as INSERM researcher, affiliated to UMR_S951 ’’INTEGRARE’’ led by Dr. Anne Galy. 

He is currently managing a team of 25 people including researchers, post-doctoral associates, PhD students, technicians focused on the development of AAV gene therapy strategies for rare diseases of genetic origin. 

Image d’exemple